How to Buy Inhibikase Therapeutics Stock
Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. , a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain.
Inhibikase Therapeutics stock last closed at $1.53, up 3.04% from the previous day, and has decreased 52.34% in one year. It has underperformed other stocks in the Biotechnology industry by 0.05 percentage points. Inhibikase Therapeutics stock is currently +14.66% from its 52-week low of $1.33, and -63.69% from its 52-week high of $4.20.
As of Dec 11, 2025, there are 75.18M IKT shares outstanding. The market cap of IKT is $114.64M. In the past 24 hours, 490,000 IKT shares were traded.
How to Buy Inhibikase Therapeutics Stock
Not sure how to invest in Inhibikase Therapeutics stock? Here's how.
- Figure out where to buy Inhibikase Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you choose where to buy Inhibikase Therapeutics stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Choose your payment method and add your details.
- Research Inhibikase Therapeutics stock: The Inhibikase Therapeutics ticker symbol is IKT. Is Inhibikase Therapeutics stock a good investment? Should you buy shares of IKT? How do IKT's underlying business fundamentals look? Do top analysts think Inhibikase Therapeutics is a good buy? Why has IKT's stock price moved recently? (Hint: Our stock market research tools can help you understand if IKT is a good stock to buy).
- Execute your IKT purchase: Decide if you will purchase IKT shares at the current market price or use a limit order to purchase IKT shares at a specific price.
- Keep an eye on your IKT investment: Create a watchlist to monitor your investment in Inhibikase Therapeutics shares.
Step 1: Figure out where to buy Inhibikase Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy IKT stock.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Technology to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the best brokerage, you'll need to fill out some personal details so you can buy IKT stock today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open your new brokerage account.
- Send your info by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have filled out your info on investing apps, your next step is to transfer the money for your investment:
Check out this video walkthrough if you need help transferring money into your new investment account.
Step 4: Research Inhibikase Therapeutics stock
After you have chosen the best place to buy Inhibikase Therapeutics stock, it's absolutely critical to evaluate their stock prior to buying, so you actually understand the risk as well as the upside.
Inhibikase Therapeutics stock quick numbers
Inhibikase Therapeutics Fundamentals
WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on IKT's stock page.
How is IKT stock valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge IKT's fair value.
Using relative valuations ratios:
- IKT may be undervalued based on its P/E ratio of 3.18x, relative to Biotechnology industry P/E ratio of 159.38x
- IKT could be undervalued based on its P/B ratio of 1.57x, relative to Biotechnology industry P/B ratio of 5.34x
You can do additional valuation analysis on IKT's stock here.
A quick look at IKT Financials
Pros:
- Total IKT debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the IKT balance sheet.
- IKT has a low debt to equity ratio of 0.09.
- IKT has $77.32M in cash and short term investments. This is enough to cover its annual cash burn of $25.63M.
- IKT has cash burn of 25629465. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the IKT balance sheet.
Is IKT stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 1 Equities analysts who track IKT, the consensus analyst rating on IKT is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are projecting on the Inhibikase Therapeutics stock forecast page.
IKT Technicals
IKT Performance Metrics
Last year, IKT revenue was $0.00. In the past 5 year, IKT's revenue has grown by -100% per year. This was slower than the Biotechnology industry average of 43.95%.
You can research IKT's earnings and revenue performance here.
Are IKT executives and large shareholders buying or selling the stock?
In the last year, insiders at IKT have bought more shares than they have sold.
Sands Capital Life Sciences Pulse Fund II LP, 10% Owner of IKT, was the latest IKT insider to buy. They bought $2,999,999.25 worth of IKT stock on Nov 21, 2025.
Get more info about who owns IKT shares here.
Can I rely on IKT as an income stream?
No, Inhibikase Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about IKT
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your IKT purchase
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are generally the best for newer investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a given dollar amount limit, use a limit order.
Hit the Open button and your broker will place the order.
If you require additional help buying stocks on eToro, watch the helpful video below:
Step 6: Keep an eye on your IKT investment
Now that you own some IKT shares, you'll want to stay up-to-date on your stock purchase.
Put IKT on a watchlist to get the latest updates about your IKT stock.
IKT Feed
How to Buy Stock in Inhibikase Therapeutics
To summarize, here are the 6 steps to buy Inhibikase Therapeutics stock:
- Figure out where to buy Inhibikase Therapeutics stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Research Inhibikase Therapeutics stock
- Execute your IKT purchase
- Keep an eye on your IKT investment
If you need a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you want to track your investment in Inhibikase Therapeutics, create a watchlist today.
Other Content You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.